Compare Gilead Sciences, Inc. (GILD) vs Strategy Inc. (MSTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Strategy Inc. — how do they compare? Gilead Sciences, Inc. trades at $146.99 (market cap $182.09B), while Strategy Inc. trades at $154.78 (market cap $61.16B). The key difference: Gilead Sciences, Inc. is far larger — about 3× Strategy Inc.'s market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Strategy Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Strategy Inc. for 112 Days on average.
| GILD | MSTR | |
|---|---|---|
Market Cap | $182.09B | $61.16B |
Volume | 4,960,247 | 21,318,561 |
Sector | Health | Technology |
52-Week High | $155.80 | $320.29 |
52-Week Low | $116.74 | $82.31 |
Typical Hold Time | 111 Days | 112 Days |
Enterprise Value | $205.15B | $79.92B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
MSTR stock trades at $151.47, down 7.95% over 24 hours, with a bullish technical signal from moving averages. The company reported a net loss of $3.85 billion for 2025 on revenue of $477.23 million, with a deeply negative net income margin of -6,102.96%. Despite severe profitability challenges, analyst consensus remains optimistic with a $252 price target, and recent news highlights significant stock volatility tied to Bitcoin market movements.
The outlook is bifurcated: strong analyst buy ratings and a high price target suggest upside potential, but fundamental weaknesses including persistent losses and negative cash flow from operations pose substantial risks. Investment appeal hinges on speculative sentiment rather than current financial health, with volatility expected to continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →
